Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Lucid Diagnostics (LUCD) EBITDA Margin (2022 - 2025)

Historic EBITDA Margin for Lucid Diagnostics (LUCD) over the last 4 years, with Q3 2025 value amounting to 971.02%.

  • Lucid Diagnostics' EBITDA Margin rose 267700.0% to 971.02% in Q3 2025 from the same period last year, while for Sep 2025 it was 1082.17%, marking a year-over-year decrease of 48000.0%. This contributed to the annual value of 1059.64% for FY2024, which is 9371500.0% up from last year.
  • Per Lucid Diagnostics' latest filing, its EBITDA Margin stood at 971.02% for Q3 2025, which was up 267700.0% from 948.67% recorded in Q2 2025.
  • In the past 5 years, Lucid Diagnostics' EBITDA Margin ranged from a high of 948.67% in Q2 2025 and a low of 18917.11% during Q3 2022
  • Over the past 4 years, Lucid Diagnostics' median EBITDA Margin value was 1283.96% (recorded in 2023), while the average stood at 4248.75%.
  • In the last 5 years, Lucid Diagnostics' EBITDA Margin soared by 174959000bps in 2023 and then plummeted by -4299700bps in 2025.
  • Lucid Diagnostics' EBITDA Margin (Quarter) stood at 13370.54% in 2022, then soared by 92bps to 1101.25% in 2023, then rose by 6bps to 1033.83% in 2024, then increased by 6bps to 971.02% in 2025.
  • Its last three reported values are 971.02% in Q3 2025, 948.67% for Q2 2025, and 1508.09% during Q1 2025.